Recent data from the Lung Allograft Rejection Gene expression Observational (LARGO) study provides compelling evidence that profiling gene expression in peripheral blood can detect organ rejection in lung transplant patients. Refining the Identification of Discriminatory Genes for Rejection in Lung Transplantation: The LARGO Study will be presented today by Shaf Keshavjee, M.D., Chair, Division of Thoracic Surgery, University of Toronto, and LARGO study lead, at the 27th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT).

Data from the study (Abstract 351) shows that the immune responses of lung transplant recipients can result in novel molecular signatures identifying the absence or presence of acute cellular rejection (ACR). That molecular signature can be identified using the quantitative real-time polymerase chain reaction (RT-PCR), a technology that measures the intracellular RNA levels of individual genes.

By distinguishing the patterns of gene expression in white blood cells (leukocytes), which fluctuate during the rejection of foreign tissue, PCR-based gene profiling can identify individual genes and pathways associated with the rejection status of transplanted lungs. In addition, the study shows that some of the genes whose expression changes during rejection of a transplanted lung are the same as those whose expression changes during the rejection of a transplanted heart.

Using microarray analysis, the researchers identified 259 genes that were differentially expressed for A0 and >A2 rejection grades (based on a standardized severity scale of 0-4). RT-PCR confirmed 14 of these genes as candidates for analysis, revealing a high correlation with those identified using microarray analysis. Seven of those genes were considered statistically significant.

"We are excited to confirm that new monitoring methods, such as non-invasive blood tests that determine a patient's gene expression profile, can identify those genes that are expressed during the rejection of a lung," said Dr. Keshavjee. "The data being presented at this year's ISHLT meeting shows the potential that exists to develop a non-invasive test that could alleviate the need for tens of thousands of biopsies."

Currently, uncomfortable and invasive biopsies are the standard for monitoring lung transplant recipients for acute cellular rejection. Biopsies are performed frequently in the first year post-transplant and periodically thereafter, often for the patient's lifetime.

Current data shows that 1,400 lung transplants were performed in 2006. And in recent years, approximately 83.3 percent of lung transplant patients survived one year following the transplant, while 62.8 percent survived three years and 47.3 survived five years. Transplant rejection is a primary concern for long-term survival, both immediately after surgery and through the patient's lifetime. To prevent rejection and subsequent damage to the new lungs, patients must take a lifelong regimen of immunosuppressive drugs.

About the LARGO Study

The LARGO study was initiated in April 2004 to examine the utility of molecular testing in post-transplant lung patient management. Fourteen centers from five countries and two continents are participating in this study to investigate the utility of gene expression testing for management of lung transplant recipients.

Several thousand samples have been collected in the LARGO database. The LARGO study and database provide an unparalleled resource for genomic and molecular diagnostic studies and development in lung transplantation.

The studies presented at ISHLT were sponsored by XDx, whose laboratory provides the gene expression testing service used in the investigation.

About ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. Created in 1981, the Society now includes more than 2,200 members from 45-plus countries, representing a variety of disciplines involved in the management and treatment of end-stage heart and lung disease.

ISHLT manages two vital databases. The International Heart and Lung Registry is a one-of-a-kind registry that has been collecting data since 1983 from 223 hospitals from 18 countries. The ISHLT Mechanical Circulatory Device (MCSD) database has been collecting data since 2002 with the aim of identifying patient populations who may benefit from MCSD implantation, generating predictive models for outcomes; and assessing the mechanical and biological reliability of current and future devices. In Fall 2006, ISHLT released the first international guidelines for heart failure patient management. For more information, visits ishlt.

International Society for Heart and Lung Transplantation
ishlt